scholarly journals A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes

2014 ◽  
Vol 145 (2) ◽  
pp. 381-388 ◽  
Author(s):  
Wendy Y. Chen ◽  
Anita Giobbie-Hurder ◽  
Kathryn Gantman ◽  
Jennifer Savoie ◽  
Rochelle Scheib ◽  
...  
2015 ◽  
Vol 33 (31) ◽  
pp. 3615-3620 ◽  
Author(s):  
Jun J. Mao ◽  
Marjorie A. Bowman ◽  
Sharon X. Xie ◽  
Deborah Bruner ◽  
Angela DeMichele ◽  
...  

Purpose Hot flashes are a common and debilitating symptom among survivors of breast cancer. This study aimed at evaluating the effects of electroacupuncture (EA) versus gabapentin (GP) for hot flashes among survivors of breast cancer, with a specific focus on the placebo and nocebo effects. Patients and Methods We conducted a randomized controlled trial involving 120 survivors of breast cancer experiencing bothersome hot flashes twice per day or greater. Participants were randomly assigned to receive 8 weeks of EA or GP once per day with validated placebo controls (sham acupuncture [SA] or placebo pills [PPs]). The primary end point was change in the hot flash composite score (HFCS) between SA and PP at week 8, with secondary end points including group comparisons and additional evaluation at week 24 for durability of treatment effects. Results By week 8, SA produced significantly greater reduction in HFCS than did PP (−2.39; 95% CI, −4.60 to −0.17). Among all treatment groups, the mean reduction in HFCS was greatest in the EA group, followed by SA, GP, and PP (−7.4 v −5.9 v −5.2 v −3.4; P = < .001). The pill groups had more treatment-related adverse events than did the acupuncture groups: GP (39.3%), PP (20.0%), EA (16.7%), and SA (3.1%), with P = .005. By week 24, HFCS reduction was greatest in the EA group, followed by SA, PP, and GP (−8.5 v −6.1 v −4.6 v −2.8; P = .002). Conclusion Acupuncture produced larger placebo and smaller nocebo effects than did pills for the treatment of hot flashes. EA may be more effective than GP, with fewer adverse effects for managing hot flashes among breast cancer survivors; however, these preliminary findings need to be confirmed in larger randomized controlled trials with long-term follow-up.


2009 ◽  
Vol 27 (3) ◽  
pp. 352-359 ◽  
Author(s):  
Ellen B. Gold ◽  
John P. Pierce ◽  
Loki Natarajan ◽  
Marcia L. Stefanick ◽  
Gail A. Laughlin ◽  
...  

Purpose To determine whether a low-fat diet high in vegetables, fruit, and fiber differentially affects prognosis in breast cancer survivors with hot flashes (HF) or without HF after treatment. Patients and Methods A secondary analysis was conducted on 2,967 breast cancer survivors, age 18 to 70 years, who were randomly assigned between 1995 and 2000 in a multicenter, controlled trial of a dietary intervention to prevent additional breast cancer events and observed through June 1, 2006. We compared the dietary intervention group with a group who received five-a-day dietary guidelines. Results Independent of HF status, a substantial between-group difference among those who did and did not receive dietary guidelines was achieved and maintained at 4 years in intake of vegetable/fruit servings per day (54% higher; 10 v 6.5 servings/d, respectively), fiber (31% higher; 25.5 v 19.4 g/d, respectively), and percent energy from fat (14% lower; 26.9% v 31.3%, respectively). Adjusting for tumor characteristics and antiestrogen treatment, HF-negative women assigned to the intervention had 31% fewer events than HF-negative women assigned to the comparison group (hazard ratio [HR] = 0.69; 95% CI, 0.51 to 0.93; P = .02). The intervention did not affect prognosis in the women with baseline HFs. Furthermore, compared with HF-negative women assigned to the comparison group, HF-positive women had significantly fewer events in both the intervention (HR = 0.77; 95% CI, 0.59 to 1.00; P = .05) and comparison groups (HR = 0.65; 95% CI, 0.49 to 0.85; P = .002). Conclusion A diet with higher vegetable, fruit, and fiber and lower fat intakes than the five-a-day diet may reduce risk of additional events in HF-negative breast cancer survivors. This suggestive finding needs confirmation in a trial in which it is the primary hypothesis.


BMJ Open ◽  
2013 ◽  
Vol 3 (9) ◽  
pp. e003138 ◽  
Author(s):  
Shannon MacLaughlan David ◽  
Sandra Salzillo ◽  
Patrick Bowe ◽  
Sandra Scuncio ◽  
Bridget Malit ◽  
...  

2003 ◽  
Vol 9 (5) ◽  
pp. 431-438 ◽  
Author(s):  
Daanish Hoda ◽  
Domingo G. Perez ◽  
Charles L. Loprinzi

Sign in / Sign up

Export Citation Format

Share Document